ReviewFrontiers in oncology2019
An Update on Molecular Biology of Cutaneous T Cell Lymphoma.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Pathway-Centric Comparative Molecular Profiling of Sézary Syndrome and Primary Cutaneous CD8Cancers · 2026Article
- A Conversational Artificial Intelligence Framework for Comparative Pathway-Level Profiling of Sézary Syndrome and Primary Cutaneous CD8medRxiv : the preprint server for health sciences · 2026Article
- Review
- Conversational Artificial Intelligence-Enabled Molecular Characterization of Sézary Syndrome Reveals Distinct Pathway-Level Alterations Compared with Non-Sézary Cutaneous T-Cell Lymphoma.medRxiv : the preprint server for health sciences · 2026Article
- A digital polymerase chain reaction method targeting non-recombined T-cell receptor sequences aids in diagnosing primary cutaneous T-cell lymphomas.Journal of Cancer · 2026Article
- Integrative Mutational Landscape of Mycosis Fungoides Using a National Genomics Repository.Cancers · 2025Article
- Diagnostic Utility of Molecular Analysis in Cutaneous T-Cell Lymphoma: Tunisian Series on Clonality of TCRG Gene Rearrangement.South Asian journal of cancer · 2025Article
- Single-cell RNA sequencing comparison of CD4+, CD8+ and T-cell receptor γδ+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes.The British journal of dermatology · 2025Article
- RUNX2 as a novel biomarker for early identification of patients progressing to advanced-stage mycosis fungoides.Frontiers in oncology · 2024Article
- Paediatric Mycosis Fungoides: Clinical Variants, Treatment Modalities and Response to Therapy.Acta dermato-venereologica · 2023Article
- Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.JCI insight · 2023Article
- Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.Healthcare (Basel, Switzerland) · 2023Review
- Molecular techniques drive cutting edge advancements in management of cutaneous T cell lymphoma.Frontiers in immunology · 2023Review
- Utility of T-cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events.Frontiers in medicine · 2023Article
- Immunosequencing applications in cutaneous T-cell lymphoma.Frontiers in immunology · 2023Review
- Article
- Review
- Cutaneous T cell lymphoma.Nature reviews. Disease primers · 2021Review
- Reactive Langerhans Cell Proliferation Mimicking Langerhans Cell Histiocytosis in Association with Sézary Syndrome: A Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2021Article
- Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous T cell lymphomas represent a heterogenous group of lymphoproliferative disorders defined by clonal proliferation of T cells present in the skin. The latest WHO classification in 2016 and WHO-EORTC classification in 2018 has updated the classification of these entities based on the molecular profile. Research in the field of molecular genetics of CTCL has allowed a better understanding of the biology of these tumors and has helped to identify potential targets for therapy that can be tailored to individual patients. In this review, we discuss the latest developments in the molecular profile of CTCLs including biomarkers for diagnosis, prognosis, and potential therapeutic targets. We have also touched upon the utility of various molecular diagnostic modalities. For the purpose of this review, we researched papers in PubMed indexed journals in English literature published in the past 20 years using keywords CTCL, mycosis fungoides, molecular profile, molecular diagnosis, whole genome profile, genomic landscape, TCR clonality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.